Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib

Journal of Clinical Oncology

Volumn 31, Issue 19, 2013, Pages

  Sinha, Rishika ^a   Edmonds, Kim ^b   Newton Bishop, Julia ^c   Gore, Martin ^b   Larkin, James ^b   Fearfield, Louise ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; B RAF KINASE; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DIPEPTIDYL CARBOXYPEPTIDASE; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; GLUTAMIC ACID; INDOLE DERIVATIVE; SULFONAMIDE; VALINE;

ADULT; ANALGESIA; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CONJUNCTIVITIS; DRUG DOSE REDUCTION; DRUG ERUPTION; ENZYME BLOOD LEVEL; ERYTHEMA NODOSUM; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; INFLAMMATORY CELL; MALE; MELANOMA; METASTATIC MELANOMA; PANNICULITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PRIORITY JOURNAL; STREPTOLYSIN TITER; CHEMICALLY INDUCED DISORDER; DIFFERENTIAL DIAGNOSIS; DRUG ANTAGONISM; GENETICS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; POINT MUTATION; SKIN TUMOR;

ADULT; ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; ERYTHEMA NODOSUM; FEMALE; GLUTAMIC ACID; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PANNICULITIS; POINT MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES; VALINE;

EID: 85047687738     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.8307     Document Type: Article

References (8)

1. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
2. Brose MS, Volpe P, Feldman M, et al: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997-7000, 2002
3. Loewe R, Kittler H, Fischer G, et al: BRAF kinase gene V599E mutation in growing melanocytic lesions. J Invest Dermatol 123:733-736, 2004
4. Ugurel S, Thirumaran RK, Bloethner S, et al: B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLOS One 2:e236, 2007
5. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
6. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
7. Sosman JA, Kim KB, Schuchter L, et al: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-714, 2012
8. Zimmer L, Livingstone E, Hillen U, et al: Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 148:357-361, 2012